It can take a long time to create a new vaccine and at the same time, there have been many evolutions and new strains of the ...

By updating the genetic code inside mRNA vaccines every year, scientists can keep population-level immunity aligned with ...

Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51) Narrows 2025 projected ...

A new lipid nanoparticle could make mRNA vaccines more powerful and potentially lower the cost per vaccine dose.

SHUTDOWN’S END — The Senate overcame a key procedural hurdle Sunday to set up a vote Monday on a House bill to fund the government and end the nearly six week government shutdown. Senators also agreed ...

Pfizer has fended off Nova Nordisk for control of the next-gen weight-loss drug developer Metsera. Meanwhile, Resmed watches ...

NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it has received approval to Start Phase II Clinical Trial of NV-387 for the Treatment of MPox by the Regulatory Agency ...

Adrian Towse, Emeritus Director and Visiting Senior Research Fellow at OHE looks back at his journey and impact in health economics research.

Q3 2025 Management View CEO Joseph Payne reported that interim Phase II data for ARCT-032, the company’s mRNA therapeutic candidate for cystic fibrosis (CF), showed "treatment with inhaled ...

Epidemiologist Michael Osterholm talks about efforts by the Center for Infectious Disease Research and Policy to inform ...

The greater part of third quarter earnings results is behind us, though notable reports from CoreWeave , The Walt Disney ...